COHEN & STEERS INC (CNS) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:CNS - US19247A1007 - Common Stock
63.77 USD
+1.01 (+1.61%)
63.77 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to CNS. CNS was compared to 237 industry peers in the Capital Markets industry. While CNS has a great profitability rating, there are some minor concerns on its financial health. CNS is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CNS had positive earnings in the past year.
In the past year CNS has reported a negative cash flow from operations.
CNS had positive earnings in each of the past 5 years.
Each year in the past 5 years CNS had a positive operating cash flow.
1.2 Ratios
CNS has a Return On Assets of 20.48%. This is amongst the best in the industry. CNS outperforms 98.31% of its industry peers.
The Return On Equity of CNS (29.83%) is better than 96.20% of its industry peers.
The Return On Invested Capital of CNS (24.24%) is better than 98.31% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CNS is significantly above the industry average of 6.96%.
The last Return On Invested Capital (24.24%) for CNS is well below the 3 year average (28.30%), which needs to be investigated, but indicates that CNS had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.48% | ||
| ROE | 29.83% | ||
| ROIC | 24.24% |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
1.3 Margins
CNS has a better Profit Margin (29.73%) than 74.26% of its industry peers.
In the last couple of years the Profit Margin of CNS has declined.
The Operating Margin of CNS (33.83%) is better than 65.40% of its industry peers.
In the last couple of years the Operating Margin of CNS has declined.
CNS's Gross Margin of 88.60% is amongst the best of the industry. CNS outperforms 92.83% of its industry peers.
In the last couple of years the Gross Margin of CNS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.83% | ||
| PM (TTM) | 29.73% | ||
| GM | 88.6% |
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
2. Health
2.1 Basic Checks
Compared to 1 year ago, CNS has more shares outstanding
Compared to 5 years ago, CNS has more shares outstanding
There is no outstanding debt for CNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 8.97 indicates that CNS is not in any danger for bankruptcy at the moment.
CNS's Altman-Z score of 8.97 is amongst the best of the industry. CNS outperforms 93.67% of its industry peers.
CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.97 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 0.79 indicates that CNS may have some problems paying its short term obligations.
CNS has a Current ratio of 0.79. This is in the lower half of the industry: CNS underperforms 64.56% of its industry peers.
A Quick Ratio of 0.79 indicates that CNS may have some problems paying its short term obligations.
CNS has a worse Quick ratio (0.79) than 64.13% of its industry peers.
CNS does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.79 | ||
| Quick Ratio | 0.79 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 8.87% over the past year.
CNS shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.50% yearly.
CNS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.13%.
CNS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.72% yearly.
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
Revenue 1Y (TTM)11.13%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%
3.2 Future
Based on estimates for the next years, CNS will show a small growth in Earnings Per Share. The EPS will grow by 7.68% on average per year.
The Revenue is expected to grow by 7.21% on average over the next years.
EPS Next Y4.56%
EPS Next 2Y8.74%
EPS Next 3Y8.1%
EPS Next 5Y7.68%
Revenue Next Year7.44%
Revenue Next 2Y8.98%
Revenue Next 3Y7.58%
Revenue Next 5Y7.21%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CNS is valuated rather expensively with a Price/Earnings ratio of 20.77.
Compared to the rest of the industry, the Price/Earnings ratio of CNS is on the same level as its industry peers.
When comparing the Price/Earnings ratio of CNS to the average of the S&P500 Index (26.15), we can say CNS is valued slightly cheaper.
With a Price/Forward Earnings ratio of 18.41, CNS is valued on the expensive side.
The rest of the industry has a similar Price/Forward Earnings ratio as CNS.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.12, CNS is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.77 | ||
| Fwd PE | 18.41 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CNS is valued a bit cheaper than the industry average as 78.48% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 15.91 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CNS does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of CNS may justify a higher PE ratio.
PEG (NY)4.55
PEG (5Y)8.32
EPS Next 2Y8.74%
EPS Next 3Y8.1%
5. Dividend
5.1 Amount
CNS has a Yearly Dividend Yield of 4.17%, which is a nice return.
Compared to an average industry Dividend Yield of 8.60, CNS has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.41, CNS pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.17% |
5.2 History
The dividend of CNS decreases each year by -7.12%.
CNS has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of CNS decreased in the last 3 years.
Dividend Growth(5Y)-7.12%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
CNS pays out 76.25% of its income as dividend. This is not a sustainable payout ratio.
DP76.25%
EPS Next 2Y8.74%
EPS Next 3Y8.1%
63.77
+1.01 (+1.61%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners60.28%
Inst Owner Change-5.95%
Ins Owners22.51%
Ins Owner Change3.24%
Market Cap3.25B
Revenue(TTM)552.10M
Net Income(TTM)164.16M
Analysts48
Price Target81.26 (27.43%)
Short Float %6.39%
Short Ratio5.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.17% |
Yearly Dividend2.39
Dividend Growth(5Y)-7.12%
DP76.25%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.39%
Min EPS beat(2)-4.27%
Max EPS beat(2)3.48%
EPS beat(4)1
Avg EPS beat(4)-0.86%
Min EPS beat(4)-4.27%
Max EPS beat(4)3.48%
EPS beat(8)3
Avg EPS beat(8)-0.49%
EPS beat(12)5
Avg EPS beat(12)0.41%
EPS beat(16)9
Avg EPS beat(16)1.94%
Revenue beat(2)1
Avg Revenue beat(2)-0.16%
Min Revenue beat(2)-1.18%
Max Revenue beat(2)0.85%
Revenue beat(4)2
Avg Revenue beat(4)-2.44%
Min Revenue beat(4)-11.33%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-1.39%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.14%
PT rev (3m)1.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.48%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.85%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.77 | ||
| Fwd PE | 18.41 | ||
| P/S | 5.89 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.91 | ||
| P/tB | 6.13 | ||
| EV/EBITDA | 15.91 |
EPS(TTM)3.07
EY4.81%
EPS(NY)3.46
Fwd EY5.43%
FCF(TTM)-1.84
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS10.83
BVpS10.79
TBVpS10.4
PEG (NY)4.55
PEG (5Y)8.32
Graham Number27.3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.48% | ||
| ROE | 29.83% | ||
| ROCE | 31.59% | ||
| ROIC | 24.24% | ||
| ROICexc | 29.06% | ||
| ROICexgc | 32.58% | ||
| OM | 33.83% | ||
| PM (TTM) | 29.73% | ||
| GM | 88.6% | ||
| FCFM | N/A |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
ROICexc(3y)52.58%
ROICexc(5y)66.96%
ROICexgc(3y)63.61%
ROICexgc(5y)82.87%
ROCE(3y)36.88%
ROCE(5y)49.77%
ROICexgc growth 3Y-36.94%
ROICexgc growth 5Y-14.2%
ROICexc growth 3Y-34.4%
ROICexc growth 5Y-13.57%
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
F-Score5
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 63.99% | ||
| Cap/Sales | 1.34% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.79 | ||
| Quick Ratio | 0.79 | ||
| Altman-Z | 8.97 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)429.54%
Cap/Depr(5y)277.84%
Cap/Sales(3y)4.88%
Cap/Sales(5y)3.14%
Profit Quality(3y)59.63%
Profit Quality(5y)81.14%
High Growth Momentum
Growth
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
EPS Next Y4.56%
EPS Next 2Y8.74%
EPS Next 3Y8.1%
EPS Next 5Y7.68%
Revenue 1Y (TTM)11.13%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%
Revenue Next Year7.44%
Revenue Next 2Y8.98%
Revenue Next 3Y7.58%
Revenue Next 5Y7.21%
EBIT growth 1Y15.71%
EBIT growth 3Y-12.76%
EBIT growth 5Y1.55%
EBIT Next Year17.56%
EBIT Next 3Y18.41%
EBIT Next 5Y13.32%
FCF growth 1Y-175.84%
FCF growth 3Y-29.26%
FCF growth 5Y-9.31%
OCF growth 1Y-150.56%
OCF growth 3Y-26.44%
OCF growth 5Y-7.32%
COHEN & STEERS INC / CNS FAQ
What is the ChartMill fundamental rating of COHEN & STEERS INC (CNS) stock?
ChartMill assigns a fundamental rating of 6 / 10 to CNS.
Can you provide the valuation status for COHEN & STEERS INC?
ChartMill assigns a valuation rating of 3 / 10 to COHEN & STEERS INC (CNS). This can be considered as Overvalued.
Can you provide the profitability details for COHEN & STEERS INC?
COHEN & STEERS INC (CNS) has a profitability rating of 8 / 10.
What are the PE and PB ratios of COHEN & STEERS INC (CNS) stock?
The Price/Earnings (PE) ratio for COHEN & STEERS INC (CNS) is 20.77 and the Price/Book (PB) ratio is 5.91.
What is the expected EPS growth for COHEN & STEERS INC (CNS) stock?
The Earnings per Share (EPS) of COHEN & STEERS INC (CNS) is expected to grow by 4.56% in the next year.